1. Signaling Pathways
  2. Immunology/Inflammation
  3. Interleukin Related
  4. IL-23 Isoform
  5. IL-23 Inhibitor

IL-23 Inhibitor

IL-23 Inhibitors (9):

Cat. No. Product Name Effect Purity
  • HY-117287
    Deucravacitinib
    Inhibitor 99.79%
    Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain.
  • HY-14644
    Apilimod
    Inhibitor 99.55%
    Apilimod (STA 5326) is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively.
  • HY-15982
    APY0201
    Inhibitor ≥98.0%
    APY0201 is a potent PIKfyve inhibitor, which inhibits the conversion of PtdIns3P to PtdIns(3,5)P2 in the presence of in the presence of [33P]ATP with an IC50 of 5.2 nM.
  • HY-14644A
    Apilimod mesylate
    Inhibitor 99.83%
    Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively.
  • HY-P9931
    Guselkumab
    Inhibitor 98.37%
    Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit.
  • HY-P99248
    Risankizumab
    Inhibitor
    Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM).
  • HY-P99485
    Brazikumab
    Inhibitor
    Brazikumab (AMG 139) is a human IgG2 monoclonal antibody, selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23.
  • HY-P99486
    Briakinumab
    Inhibitor
    Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody.
  • HY-126252
    A-9758
    Inhibitor
    A-9758 is a RORγ ligand and a potent, selective RORγt inverse agonist (IC50=5 nM), and exhibits robust potency against IL-17A release.